Profile data is unavailable for this security.
About the company
HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.
- Revenue in HKD (TTM)6.56bn
- Net income in HKD788.39m
- Incorporated2000
- Employees1.99k
- LocationHUTCHMED (China) Ltd48Th Floor, Cheung Kong Center2 Queen's Road Central Hong KongHKG
- Phone+852 21281188
- Fax+852 21281778
- Websitehttps://www.hutch-med.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SSY Group Ltd | 6.46bn | 1.32bn | 13.95bn | 5.60k | 10.62 | 2.01 | 7.98 | 2.16 | 0.4427 | 0.4427 | 2.17 | 2.33 | 0.5637 | 3.00 | 3.01 | 1,154,109.00 | 11.59 | 10.51 | 15.58 | 14.03 | 56.01 | 58.72 | 20.57 | 18.62 | 1.60 | 29.61 | 0.317 | 38.56 | 0.4505 | 9.10 | 17.44 | 7.66 | 3.94 | 13.56 |
| Simcere Pharmaceutical Group Ltd | 7.14bn | 772.30m | 14.88bn | 7.03k | 19.67 | 1.91 | 13.45 | 2.08 | 0.2897 | 0.2897 | 2.74 | 2.98 | 0.6106 | 3.53 | 2.65 | 1,016,039.00 | 6.60 | 10.17 | 8.94 | 15.60 | 75.43 | 78.82 | 10.80 | 17.50 | 1.87 | 0.9742 | 0.1652 | 46.68 | 4.49 | 7.92 | -23.22 | -0.5213 | 23.93 | -- |
| Grand Pharmaceutical Group Ltd | 10.53bn | 1.88bn | 15.83bn | 10.53k | 8.33 | 1.03 | 6.92 | 1.50 | 0.5356 | 0.5356 | 3.00 | 4.33 | 0.4692 | 2.94 | 10.26 | 999,581.40 | 8.45 | 10.09 | 11.66 | 14.01 | 61.96 | 61.97 | 18.00 | 22.35 | 0.9819 | 22.96 | 0.1831 | 26.94 | 10.12 | 12.06 | -9.59 | 21.41 | 5.69 | 24.77 |
| 3SBio Inc | 8.45bn | 1.67bn | 16.05bn | 5.41k | 9.75 | 1.04 | 7.73 | 1.90 | 0.6747 | 0.6747 | 3.46 | 6.32 | 0.3426 | 1.58 | 7.01 | 1,560,726.00 | 6.95 | 7.44 | 9.03 | 9.29 | 84.98 | 82.91 | 20.30 | 21.50 | 2.26 | 22.72 | 0.2266 | -- | 13.84 | 11.26 | -19.13 | 3.94 | 8.78 | -- |
| The United Laboratories Intl. Hldgs Ltd. | 14.85bn | 2.92bn | 17.26bn | 15.00k | 5.91 | 1.25 | 4.89 | 1.16 | 1.61 | 1.61 | 8.17 | 7.57 | 0.6871 | 3.36 | 6.15 | 989,725.80 | 13.51 | 7.89 | 20.52 | 12.64 | 46.11 | 44.17 | 19.66 | 12.73 | 1.74 | -- | 0.1055 | 28.99 | 21.22 | 12.84 | 70.85 | 31.66 | 24.19 | 14.67 |
| China Traditional Chinese Med Hldg CoLtd | 19.58bn | 1.39bn | 21.65bn | 17.30k | 15.59 | 0.9471 | 8.02 | 1.11 | 0.2758 | 0.2758 | 3.89 | 4.54 | 0.4985 | 1.47 | 2.16 | 1,131,630.00 | 3.84 | 4.60 | 5.85 | 7.07 | 51.18 | 57.07 | 7.70 | 9.77 | 1.48 | 9.83 | 0.1773 | 17.35 | 26.69 | 9.99 | 68.11 | -2.24 | -12.75 | -- |
| Genscript Biotech Corp | 6.57bn | -746.91m | 26.21bn | 6.94k | -- | 2.40 | -- | 3.99 | -0.3545 | -0.3545 | 3.11 | 5.13 | 0.283 | 7.59 | 5.45 | 946,742.30 | -11.97 | -18.34 | -18.27 | -26.15 | 48.78 | 54.68 | -42.30 | -64.91 | 4.65 | -- | 0.1694 | -- | 34.17 | 29.44 | 57.91 | -- | 17.14 | -- |
| HUTCHMED (China) Ltd | 6.56bn | 788.39m | 26.88bn | 1.99k | 34.32 | 4.70 | 31.43 | 4.10 | 0.8989 | 0.8989 | 7.63 | 6.56 | 0.7258 | 7.19 | 7.69 | 3,297,577.00 | 8.76 | -14.35 | 13.36 | -20.43 | 54.12 | 36.57 | 12.06 | -31.44 | 2.60 | -- | 0.1038 | -- | 96.52 | 31.38 | 127.93 | -- | 38.65 | -- |
| RemeGen Co Ltd | 1.16bn | -1.63bn | 26.98bn | 3.62k | -- | 4.34 | -- | 23.20 | -3.03 | -3.03 | 2.16 | 6.91 | 0.1864 | 0.4005 | 4.31 | 321,647.10 | -26.17 | -18.66 | -31.75 | -23.75 | 76.48 | 81.94 | -140.43 | -102.88 | 1.31 | -64.32 | 0.2682 | -- | 40.16 | 148.65 | -51.30 | -- | 59.07 | -- |
| WuXi XDC Cayman Inc | 2.29bn | 306.36m | 27.60bn | 1.18k | 82.32 | 4.68 | 74.56 | 12.03 | 0.28 | 0.28 | 2.13 | 4.92 | -- | -- | -- | 1,948,047.00 | -- | -- | -- | -- | 26.35 | -- | 13.35 | -- | 4.03 | -- | 0.0005 | -- | 114.44 | -- | 82.07 | -- | -- | -- |
| Sichuan Kelun-Biotech Biophrmctcl Co Ltd | 1.66bn | -620.35m | 36.78bn | 1.42k | -- | 14.61 | -- | 22.10 | -2.79 | -2.79 | 7.59 | 11.48 | -- | -- | -- | 1,176,323.00 | -- | -- | -- | -- | 49.28 | -- | -37.27 | -- | 2.47 | -34.90 | 0.0251 | -- | 91.62 | -- | 6.81 | -- | -- | -- |
Data as of May 03 2024. Currency figures normalised to HUTCHMED (China) Ltd's reporting currency: Hong Kong Dollar HKD
19.45%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| M&G Investment Management Ltd.as of 02 Nov 2023 | 43.17m | 4.96% |
| Capital Research & Management Co. (Global Investors)as of 11 Nov 2022 | 31.19m | 3.58% |
| Canada Pension Plan Investment Boardas of 15 May 2023 | 25.86m | 2.97% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 16.51m | 1.90% |
| Capital Research & Management Co. (International Investors)as of 30 Dec 2022 | 13.10m | 1.50% |
| FIL Investment Management (Hong Kong) Ltd.as of 29 Feb 2024 | 9.17m | 1.05% |
| Capital International, Inc.as of 11 Nov 2022 | 8.79m | 1.01% |
| Bank of China Investment Management Co., Ltd.as of 30 Jun 2023 | 8.70m | 1.00% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 6.93m | 0.80% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 6.05m | 0.70% |
More ▼
Data from 30 Jun 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
